The document contains performance review charts related to GlaxoSmithKline's quarterly and annual Core EPS growth, Vaccines CER growth rates, and Adavair CER growth rates. The data is not legible at the current resolution and requests for higher-resolution images or underlying data are made.
documents/vol00010-efta01457561-pdf.pdf
{"title":"Performance Review Charts","document_date":"2016-05-11","document_type":"tabular","key_locations":["London"],"key_organizations":["GlaxoSmithKline","Deutsche Bank AG"],"reference_numbers":["DB-SDNY-0117158","SDNY_GM_00263342","EFTA01457561"]}